RBC reiterates Medicis at outperform

Medicis Pharmaceutical Corp. was reiterated by RBC Capital Markets analyst Ken Trbovich at outperform, above average risk, with a $39 price target. IMS Health data shows Solodyn Rx prescriptions nearly doubled to 2,594 in the most recently reported week. Prescriptions should continue to rise with the seasonally strong back-to-school months of August and September, according to the analyst. Shares of the Scottsdale, Ariz.-based pharmaceutical company were down 74 cents, or 2.69%, at $26.82, on volume of 1,663,100 shares versus the three-month running average of 1,138,630 shares. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.